WILMINGTON, Del. - Phreesia (NYSE:PHR), a company specializing in patient intake and engagement, has reported notable success in its cancer prevention campaigns, particularly in increasing the rates of cancer screenings among patients. The company's recent analysis indicates that providing patients with relevant information about cancer prevention at the point of care leads to a higher likelihood of them requesting screenings.
During a breast cancer awareness initiative, Phreesia reached 268,000 patients over 10 days. The campaign's effectiveness was evident as over 80% of patients surveyed found the information helpful. Notably, 32% of patients at one health system requested a mammogram appointment following the campaign. The data also showed that the campaign was particularly effective among minority groups, with 94% of Black respondents and 89% of non-white respondents acknowledging the helpfulness of the content.
The analysis extended to other types of cancer as well. In a colorectal cancer campaign, 40% of respondents identified themselves as high-risk, signaling the need for prompt screenings. Additionally, a health system inquired about cervical cancer screenings with more than 4,800 women, of which 30% expressed intent to discuss screening options with their healthcare providers. In a separate lung cancer screening campaign, patients aged 50-80 with a history of smoking were 234% more likely to get screened after being exposed to the campaign's message.
David Linetsky, Senior Vice President of Life Sciences at Phreesia, emphasized the importance of patient education at the point of care in achieving better health outcomes. The company's digital intake platform has been instrumental in sharing vital cancer screening information, especially after screening rates dropped significantly during the COVID-19 pandemic.
The company, founded in 2005, has enabled over 120 million patient visits in 2022.
This report is based on a press release statement from Phreesia.
InvestingPro Insights
Phreesia's (NYSE:PHR) proactive approach in patient engagement and cancer prevention has been reflected not only in their campaigns but also in their financial performance. With a market capitalization of $1.53 billion, the company has shown a solid revenue growth of 28.79% over the last twelve months as of Q3 2024, indicating their strategies may be resonating with a growing number of healthcare providers.
One of the key InvestingPro Tips for Phreesia is the aggressive share buyback strategy management has been employing. This could signal confidence from the leadership in the company's future prospects. Additionally, Phreesia has been trading at a high Price / Book multiple of 5.79, which may reflect the market's valuation of the company's assets and growth potential, despite not being profitable over the last twelve months.
InvestingPro Data also shows a strong return of 72.17% over the last three months, suggesting that investors are optimistic about the company's performance and future outlook. However, it's important to note that analysts do not anticipate the company will be profitable this year, and Phreesia operates with a moderate level of debt. These factors should be considered when evaluating the company's financial health.
For readers interested in a deeper dive into Phreesia's financials and future prospects, there are additional InvestingPro Tips available at https://www.investing.com/pro/PHR. Use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and discover more insights that could guide your investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.